Theranos
Theranos Blood Testing Fraud
Estimated impact: $9B valuation to zero; potential patient harm from inaccurate results
Elizabeth Holmes founded Theranos claiming its Edison device could run hundreds of blood tests from a single finger prick. The technology never worked as claimed — most tests were run on modified commercial machines. A Wall Street Journal investigation by John Carreyrou in 2015 exposed the fraud. The company's $9 billion valuation went to zero. Holmes was convicted of four counts of wire fraud in 2022.
Decision context
Whether investors, board members, and retail pharmacy partners (Walgreens) should have demanded independent validation of Theranos's core technology claims before committing billions in capital and customer trust.
Biases present in the decision
Toxic combinations
- Echo Chamber
- Optimism Trap
Reference class base rates
Across all 146 curated case studies in our library:
Lessons learned
- A board stacked with political luminaries (Kissinger, Shultz, Mattis) but zero medical device experts created the ultimate authority bias — credibility without competence.
- Walgreens invested $140 million without ever independently validating the core technology, relying instead on Holmes's reputation and board prestige.
- When employees raised concerns, they were silenced with NDAs and threats — dissent suppression is the strongest predictor of catastrophic fraud.
Source: John Carreyrou, "Bad Blood: Secrets and Lies in a Silicon Valley Startup" (2018); U.S. v. Holmes, N.D. Cal. No. 18-cr-00258; SEC v. Theranos Inc. and Elizabeth A. Holmes (2018) (News Investigation)
See what we'd flag in your next strategic memo.
Upload a strategic memo or board deck. Get the same bias audit you just saw for Theranos, on your own high-stakes call, in under 60 seconds.
Or leave your email, we'll run a strategic memo of your choosing and send the readout within a business day.
Ready to audit your own memo right now? Create a free account →